pt en es

Reagentes e instrumentos para imunologia, biologia celular e biologia molecular.

Celecoxib [169590-42-5]

Imprimir

Referência HY-14398-1g

Tamanho : 1g

Contactar o distribuidor local :

Telefone : +1 850 650 7790

Marca : MedChemExpress

Solicitar mais informações

Contactar o distribuidor local :

Telefone : +1 850 650 7790

Description

Celecoxib,a selective and BBB-permeable non-steroidal anti-inflammatory drug (NSAID), is a selective COX-2 inhibitor with an IC₅₀ of 40 nM.

IC₅₀ & Target^[1]

COX-2

40 nM (IC₅₀)

COX-1

15 μM (IC₅₀)

Cellular Effect

Cell Line	Type	Value	Description	References
A2780	IC₅₀	18.1 μM Compound: Cel	Cytotoxicity against human A2780 cells assessed as inhibition in cell growth incubated for 72 hrs by MTT assay Cytotoxicity against human A2780 cells assessed as inhibition in cell growth incubated for 72 hrs by MTT assay	[PMID: 37567059]
A549	IC₅₀	11.04 μM Compound: Celecoxib	Antiproliferative activity against human A549 cells incubated for 48 hrs by MTT assay Antiproliferative activity against human A549 cells incubated for 48 hrs by MTT assay	[PMID: 30877972]
A549	IC₅₀	15.6 μM Compound: Celecoxib	Antitumor activity against human A549 cells assessed as inhibition of cell proliferation after 48 hrs by MTT assay Antitumor activity against human A549 cells assessed as inhibition of cell proliferation after 48 hrs by MTT assay	[PMID: 23353741]
A549	IC₅₀	15.64 μM Compound: Celecoxib	Antiproliferative activity against human A549 cells after 24 hrs by MTT assay Antiproliferative activity against human A549 cells after 24 hrs by MTT assay	[PMID: 27349331]
A549	IC₅₀	16.08 μM Compound: Celecoxib	Antiproliferative activity against human A549 cells after 48 hrs by MTT assay Antiproliferative activity against human A549 cells after 48 hrs by MTT assay	[PMID: 30031652]
A549	IC₅₀	16.3 μM Compound: Celecoxib	Antiproliferative activity against human A549 cells assessed as inhibition of cell proliferation Antiproliferative activity against human A549 cells assessed as inhibition of cell proliferation	[PMID: 34217828]
A549	IC₅₀	17.5 μM Compound: Celecoxib	Antiproliferative activity against human A549 cells assessed as cell growth inhibition measured after 72 hrs by SRB assay Antiproliferative activity against human A549 cells assessed as cell growth inhibition measured after 72 hrs by SRB assay	[PMID: 32485532]
A549	IC₅₀	2.15 μM Compound: Celecoxib	Antiproliferative activity against human A549 cells incubated for 48 hrs by MTT assay Antiproliferative activity against human A549 cells incubated for 48 hrs by MTT assay	[PMID: 26346367]
A549	IC₅₀	57.87 μM Compound: Celecoxib	Cytotoxicity against human A549 cells assessed as reduction in cell viability measured after 72 hrs by MTS assay Cytotoxicity against human A549 cells assessed as reduction in cell viability measured after 72 hrs by MTS assay	[PMID: 35134642]
A549	IC₅₀	7.68 μM Compound: Celecoxib	Antiproliferative activity against human A549 cells after 48 hrs by MTT assay Antiproliferative activity against human A549 cells after 48 hrs by MTT assay	[PMID: 28720504]
B16-F10	IC₅₀	13.27 μM Compound: Celecoxib	Antiproliferative activity against mouse B16F10 cells incubated for 48 hrs by MTT assay Antiproliferative activity against mouse B16F10 cells incubated for 48 hrs by MTT assay	[PMID: 30877972]
B16-F10	IC₅₀	14.36 μM Compound: Celecoxib	Antiproliferative activity against mouse B16F10 cells after 24 hrs by MTT assay Antiproliferative activity against mouse B16F10 cells after 24 hrs by MTT assay	[PMID: 27349331]
B16-F10	IC₅₀	16.2 μM Compound: Celecoxib	Antiproliferative activity against mouse B16-F10 cells assessed as inhibition of cell proliferation Antiproliferative activity against mouse B16-F10 cells assessed as inhibition of cell proliferation	[PMID: 34217828]
B16-F10	IC₅₀	19.15 μM Compound: Celecoxib	Antiproliferative activity against mouse B16F10 cells after 48 hrs by MTT assay Antiproliferative activity against mouse B16F10 cells after 48 hrs by MTT assay	[PMID: 30031652]
B16-F10	IC₅₀	4.56 μM Compound: Celecoxib	Antiproliferative activity against mouse B16F10 cells after 24 hrs by MTT assay Antiproliferative activity against mouse B16F10 cells after 24 hrs by MTT assay	[PMID: 25866240]
B16-F10	IC₅₀	85.6 μM Compound: Celecoxib	Antiproliferative activity against mouse B16F10 cells after 48 hrs by MTT colorimetric assay Antiproliferative activity against mouse B16F10 cells after 48 hrs by MTT colorimetric assay	[PMID: 22000948]
B16-F10	IC₅₀	85.9 μM Compound: Celecoxib	Antitumor activity against mouse B16F10 cells assessed as inhibition of cell proliferation after 48 hrs by MTT assay Antitumor activity against mouse B16F10 cells assessed as inhibition of cell proliferation after 48 hrs by MTT assay	[PMID: 23353741]
C6	IC₅₀	> 40 μM Compound: Celecoxib	Antiproliferative activity against rat C6 cells assessed as growth inhibition incubated for 72 hrs by CCK-8 assay Antiproliferative activity against rat C6 cells assessed as growth inhibition incubated for 72 hrs by CCK-8 assay	[PMID: 34091208]
CHO	IC₅₀	0.002 μM Compound: 2, SC-58635	In vitro potency against human Prostaglandin G/H synthase 2 in transfected CHO cells. In vitro potency against human Prostaglandin G/H synthase 2 in transfected CHO cells.	[PMID: 10197970]
CHO	IC₅₀	0.002 μM Compound: Celecoxib	In vitro inhibitory potency against human COX-2 in stably transfected chinese hamster ovary (CHO) cells In vitro inhibitory potency against human COX-2 in stably transfected chinese hamster ovary (CHO) cells	[PMID: 10576684]
CHO	IC₅₀	0.002 μM Compound: Celecoxib	Inhibition of PGE-2 production in CHO cells expressing human COX-2. Inhibition of PGE-2 production in CHO cells expressing human COX-2.	[PMID: 10576685]
CHO	IC₅₀	0.002 μM Compound: Celecoxib	Inhibitory of human Prostaglandin G/H synthase 2 expressed in CHO cells. Inhibitory of human Prostaglandin G/H synthase 2 expressed in CHO cells.	[PMID: 12643942]
CHO	IC₅₀	0.036 μM Compound: celecoxib	Inhibition of COX2 expressed in CHO cells assessed as inhibition of arachidonic acid-stimulated PGE2 production by enzyme immunoassay Inhibition of COX2 expressed in CHO cells assessed as inhibition of arachidonic acid-stimulated PGE2 production by enzyme immunoassay	[PMID: 15566290]
CHO	IC₅₀	13.5 μM Compound: celecoxib	Inhibition of COX1 expressed in CHO cells assessed as inhibition of arachidonic acid-stimulated PGE2 production by enzyme immunoassay Inhibition of COX1 expressed in CHO cells assessed as inhibition of arachidonic acid-stimulated PGE2 production by enzyme immunoassay	[PMID: 15566290]
Caco-2	IC₅₀	42.74 μM Compound: Celecoxib	Antiproliferative activity against human Caco2 cells by MTT assay Antiproliferative activity against human Caco2 cells by MTT assay	[PMID: 30216848]
DU-145	IC₅₀	59.34 μM Compound: Celecoxib	Cytotoxicity against human DU-145 cells assessed as reduction in cell viability measured after 72 hrs by MTS assay Cytotoxicity against human DU-145 cells assessed as reduction in cell viability measured after 72 hrs by MTS assay	[PMID: 35134642]
HCT-116	IC₅₀	29.54 μM Compound: Celecoxib	Antiproliferative activity against human HCT116 cells by MTT assay Antiproliferative activity against human HCT116 cells by MTT assay	[PMID: 30216848]
HCT-116	IC₅₀	43.3 μM Compound: Celecoxib	Anticancer activity against human HCT116 cells after 72 hrs by MTT assay Anticancer activity against human HCT116 cells after 72 hrs by MTT assay	[PMID: 21678971]
HEK-293T	CC₅₀	54.38 μM Compound: Celecoxib	Cytotoxicity against HEK293T cells incubated for 48 hrs by MTT assay Cytotoxicity against HEK293T cells incubated for 48 hrs by MTT assay	[PMID: 26346367]
HEK-293T	CC₅₀	55.83 μM Compound: Celecoxib	Cytotoxicity against human 293T cells by MTT assay Cytotoxicity against human 293T cells by MTT assay	[PMID: 30342958]
HEK-293T	CC₅₀	72.42 μM Compound: Celecoxib	Cytotoxicity against human 293T cells after 24 hrs by MTT assay Cytotoxicity against human 293T cells after 24 hrs by MTT assay	[PMID: 25866240]
HEK-293T	IC₅₀	111.86 μM Compound: Celecoxib	Antiproliferative activity against human 293T cells after 48 hrs by MTT assay Antiproliferative activity against human 293T cells after 48 hrs by MTT assay	[PMID: 28720504]
HEK-293T	IC₅₀	224.86 μM Compound: Celecoxib	Cytotoxicity against human 293T cells after 48 hrs by MTT assay Cytotoxicity against human 293T cells after 48 hrs by MTT assay	[PMID: 30031652]
HEK-293T	IC₅₀	95.26 μM Compound: Celecoxib	Antiproliferative activity against human 293T cells after 24 hrs by MTT assay Antiproliferative activity against human 293T cells after 24 hrs by MTT assay	[PMID: 27349331]
HEK-293T	IC₅₀	97.87 μM Compound: Celecoxib	Antiproliferative activity against human 293T cells incubated for 48 hrs by MTT assay Antiproliferative activity against human 293T cells incubated for 48 hrs by MTT assay	[PMID: 30877972]
HL-60	IC₅₀	44.72 μM Compound: Celecoxib	Antiproliferative activity against human HL-60 cells assessed as reduction in cell viability incubated for 48 hrs by CCK8 assay Antiproliferative activity against human HL-60 cells assessed as reduction in cell viability incubated for 48 hrs by CCK8 assay	[PMID: 36395680]
HT-29	IC₅₀	0.7 μM Compound: Celecoxib	Cytotoxicity against COX-2 positive human HT-29 cells transfected with CD44v6shRNA assessed as growth inhibition after 48 hrs by MTT assay Cytotoxicity against COX-2 positive human HT-29 cells transfected with CD44v6shRNA assessed as growth inhibition after 48 hrs by MTT assay	[PMID: 24295787]
HT-29	IC₅₀	17.97 μM Compound: Celecoxib	Antiproliferative activity against human HT-29 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Antiproliferative activity against human HT-29 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 33477020]
HT-29	IC₅₀	18.3 μM Compound: Celecoxib	Inhibition of hyaluronan-induced CD44 antigen variant exon 6 activity in human HT-29 cells expressing Has2 assessed as decrease in cell survival after 18 hrs by MTS assay Inhibition of hyaluronan-induced CD44 antigen variant exon 6 activity in human HT-29 cells expressing Has2 assessed as decrease in cell survival after 18 hrs by MTS assay	[PMID: 23517721]
HT-29	IC₅₀	18 μg/mL Compound: Celecoxib	Antiproliferative activity against human HT-29 cells after 24 hrs by MTT assay Antiproliferative activity against human HT-29 cells after 24 hrs by MTT assay	[PMID: 22750009]
HT-29	IC₅₀	3 μM Compound: Celecoxib	Cytotoxicity against human HT-29 cells assessed as decrease in cell survival after 18 hrs by MTS assay Cytotoxicity against human HT-29 cells assessed as decrease in cell survival after 18 hrs by MTS assay	[PMID: 23517721]
HT-29	IC₅₀	32.5 μM Compound: Cel	Cytotoxicity against human HT-29 cells assessed as inhibition in cell growth incubated for 72 hrs by MTT assay Cytotoxicity against human HT-29 cells assessed as inhibition in cell growth incubated for 72 hrs by MTT assay	[PMID: 37567059]
HT-29	IC₅₀	45.5 μM Compound: celecoxib	Cytotoxicity against human HT-29 cells by MTT assay Cytotoxicity against human HT-29 cells by MTT assay	[PMID: 20804197]
HT-29	IC₅₀	5.7 μM Compound: Celecoxib	Cytotoxicity against COX-2 positive human HT-29 cells assessed as growth inhibition by CellTiter-96 AQueous assay Cytotoxicity against COX-2 positive human HT-29 cells assessed as growth inhibition by CellTiter-96 AQueous assay	[PMID: 24295787]
HT-29	IC₅₀	8.47 μM Compound: Celecoxib	Antiproliferative activity against human HT-29 cells after 48 hrs by MTT assay Antiproliferative activity against human HT-29 cells after 48 hrs by MTT assay	[PMID: 28720504]
HeLa	IC₅₀	11.06 μM Compound: Celecoxib	Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay	[PMID: 28720504]
HeLa	IC₅₀	15.68 μM Compound: Celecoxib	Antiproliferative activity against human HeLa cells incubated for 48 hrs by MTT assay Antiproliferative activity against human HeLa cells incubated for 48 hrs by MTT assay	[PMID: 30877972]
HeLa	IC₅₀	15.69 μM Compound: Celecoxib	Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay	[PMID: 30031652]
HeLa	IC₅₀	32.7 μM Compound: CXB	Cytotoxicity against human HeLa cells assessed as inhibition of cell proliferation Cytotoxicity against human HeLa cells assessed as inhibition of cell proliferation	[PMID: 36634752]
HeLa	IC₅₀	36.08 μM Compound: Celecoxib	Antiproliferative activity against human HeLa cells by MTT assay Antiproliferative activity against human HeLa cells by MTT assay	[PMID: 30216848]
HeLa	IC₅₀	58.2 μM Compound: Celecoxib	Cytotoxicity against human HeLa cells assessed as reduction in cell viability measured after 72 hrs by MTS assay Cytotoxicity against human HeLa cells assessed as reduction in cell viability measured after 72 hrs by MTS assay	[PMID: 35134642]
HeLa	IC₅₀	7.35 μM Compound: Celecoxib	Antiproliferative activity against human HeLa cells after 24 hrs by MTT assay Antiproliferative activity against human HeLa cells after 24 hrs by MTT assay	[PMID: 25866240]
HeLa	IC₅₀	7.55 μM Compound: Celecoxib	Antiproliferative activity against human HeLa cells incubated for 48 hrs by MTT assay Antiproliferative activity against human HeLa cells incubated for 48 hrs by MTT assay	[PMID: 26346367]
HeLa	IC₅₀	7.55 μM Compound: Celecoxib	Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay	[PMID: 30342958]
HeLa	IC₅₀	7.79 μM Compound: Celecoxib	Antiproliferative activity against human HeLa cells after 24 hrs by MTT assay Antiproliferative activity against human HeLa cells after 24 hrs by MTT assay	[PMID: 27349331]
HepG2	IC₅₀	0.36 μM Compound: Celecoxib	Antiproliferative activity against human HepG2 cells assessed as cell growth inhibition measured after 72 hrs by SRB assay Antiproliferative activity against human HepG2 cells assessed as cell growth inhibition measured after 72 hrs by SRB assay	[PMID: 32485532]
HepG2	IC₅₀	0.76 μM Compound: Celecoxib	Antiproliferative activity against human HepG2 cells incubated for 48 hrs by MTT assay Antiproliferative activity against human HepG2 cells incubated for 48 hrs by MTT assay	[PMID: 26346367]
HepG2	IC₅₀	0.78 μM Compound: Celecoxib	Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay	[PMID: 30342958]
HepG2	IC₅₀	10.03 μM Compound: Celecoxib	Antiproliferative activity against human HepG2 cells after 24 hrs by MTT assay Antiproliferative activity against human HepG2 cells after 24 hrs by MTT assay	[PMID: 27349331]
HepG2	IC₅₀	43.6 μM Compound: CXB	Cytotoxicity against human HepG2 cells assessed as inhibition of cell proliferation Cytotoxicity against human HepG2 cells assessed as inhibition of cell proliferation	[PMID: 36634752]
HepG2	IC₅₀	58.2 μM Compound: Celecoxib	Cytotoxicity against human HepG2 cells assessed as reduction in cell viability measured after 72 hrs by MTS assay Cytotoxicity against human HepG2 cells assessed as reduction in cell viability measured after 72 hrs by MTS assay	[PMID: 35134642]
HepG2	IC₅₀	95.5 μM Compound: Celecoxib	Antiproliferative activity against human HepG2 cells after 48 hrs by MTT colorimetric assay Antiproliferative activity against human HepG2 cells after 48 hrs by MTT colorimetric assay	[PMID: 22000948]
J774	IC₅₀	0.06 μM Compound: 1b	Inhibition of COX2 in LPS-stimulated mouse J774 cells assessed as inhibition of PGE2 production after 15 mins by radioimmunoassay Inhibition of COX2 in LPS-stimulated mouse J774 cells assessed as inhibition of PGE2 production after 15 mins by radioimmunoassay	[PMID: 18752957]
J774	IC₅₀	0.06 μM Compound: celecoxib	Inhibition of COX2 in LPS-stimulated J774 cells assessed as inhibition of PGE2 levels by radioimmunoassay Inhibition of COX2 in LPS-stimulated J774 cells assessed as inhibition of PGE2 levels by radioimmunoassay	[PMID: 17915854]
J774	IC₅₀	0.061 μM Compound: Celecoxib	Inhibition of COX-2-mediated PGE2 production in LPS-stimulated mouse J774 cells after 24 hrs by radioimmunoassay Inhibition of COX-2-mediated PGE2 production in LPS-stimulated mouse J774 cells after 24 hrs by radioimmunoassay	[PMID: 21992176]
J774	IC₅₀	0.061 μM Compound: Celecoxib	Inhibition of COX2 in mouse J774 cells assessed as inhibition of LPS-induced PGE2 production by radioimmunoassay Inhibition of COX2 in mouse J774 cells assessed as inhibition of LPS-induced PGE2 production by radioimmunoassay	[PMID: 23680444]
J774	IC₅₀	0.079 μM Compound: 1b	Inhibition of COX2-dependent PGE2 production in LPS-stimulated mouse J774 cells by RIA Inhibition of COX2-dependent PGE2 production in LPS-stimulated mouse J774 cells by RIA	[PMID: 19957931]
J774	IC₅₀	0.079 μM Compound: Celecoxib	In vitro inhibitory activity against Prostaglandin G/H synthase 2 in murine J774 cells In vitro inhibitory activity against Prostaglandin G/H synthase 2 in murine J774 cells	[PMID: 15857149]
J774	IC₅₀	3.7 μM Compound: 1b	Inhibition of COX1 in arachidonic acid-stimulated mouse J774 cells assessed as inhibition of PGE2 production after 15 mins by radioimmunoassay Inhibition of COX1 in arachidonic acid-stimulated mouse J774 cells assessed as inhibition of PGE2 production after 15 mins by radioimmunoassay	[PMID: 18752957]
J774	IC₅₀	3.7 μM Compound: celecoxib	Inhibition of COX1 in mouse J774 cells assessed as arachidonic acid-induced PGE2 levels by radio immunoassay Inhibition of COX1 in mouse J774 cells assessed as arachidonic acid-induced PGE2 levels by radio immunoassay	[PMID: 17915854]
J774	IC₅₀	3.84 μM Compound: Celecoxib	Inhibition of COX-1-mediated PGE2 production in arachidonic acid-stimulated mouse J774 cells incubated for 15 mins prior to arachidonic acid-challenge by radioimmunoassay Inhibition of COX-1-mediated PGE2 production in arachidonic acid-stimulated mouse J774 cells incubated for 15 mins prior to arachidonic acid-challenge by radioimmunoassay	[PMID: 21992176]
J774	IC₅₀	3.84 μM Compound: Celecoxib	Inhibition of COX1 in mouse J774 cells using arachidonic acid as substrate assessed as inhibition of PGE2 production incubated for 15 mins prior to substrate addition measured after 30 mins by radioimmunoassay Inhibition of COX1 in mouse J774 cells using arachidonic acid as substrate assessed as inhibition of PGE2 production incubated for 15 mins prior to substrate addition measured after 30 mins by radioimmunoassay	[PMID: 23680444]
J774	IC₅₀	5.1 μM Compound: 1b	Inhibition of COX1-dependent PGE2 production in LPS-stimulated mouse J774 cells by RIA Inhibition of COX1-dependent PGE2 production in LPS-stimulated mouse J774 cells by RIA	[PMID: 19957931]
J774	IC₅₀	5.1 μM Compound: Celecoxib	In vitro inhibitory activity against Prostaglandin G/H synthase 1 in murine J774 cells In vitro inhibitory activity against Prostaglandin G/H synthase 1 in murine J774 cells	[PMID: 15857149]
J774	IC₅₀	80 μM Compound: 1b	Inhibition of COX2-dependent PGE2 production in LPS-stimulated mouse J774 cells at 1 uM by RIA Inhibition of COX2-dependent PGE2 production in LPS-stimulated mouse J774 cells at 1 uM by RIA	[PMID: 19957931]
J774	IC₅₀	95 μM Compound: 1b	Inhibition of COX2-dependent PGE2 production in LPS-stimulated mouse J774 cells at 10 uM by RIA Inhibition of COX2-dependent PGE2 production in LPS-stimulated mouse J774 cells at 10 uM by RIA	[PMID: 19957931]
Jurkat	IC₅₀	32.13 μM Compound: Celecoxib	Antiproliferative activity against human Jurkat cells assessed as reduction in cell viability incubated for 48 hrs by CCK8 assay Antiproliferative activity against human Jurkat cells assessed as reduction in cell viability incubated for 48 hrs by CCK8 assay	[PMID: 36395680]
K562	IC₅₀	57.81 μM Compound: Celecoxib	Antiproliferative activity against human K562 cells assessed as reduction in cell viability incubated for 48 hrs by CCK8 assay Antiproliferative activity against human K562 cells assessed as reduction in cell viability incubated for 48 hrs by CCK8 assay	[PMID: 36395680]
L02	CC₅₀	78.2 μM Compound: Celecoxib	Cytotoxicity against human LO2 cells by MTT assay Cytotoxicity against human LO2 cells by MTT assay	[PMID: 30342958]
L02	IC₅₀	98.15 μM Compound: Celecoxib	Antiproliferative activity against human LO2 cells after 24 hrs by MTT assay Antiproliferative activity against human LO2 cells after 24 hrs by MTT assay	[PMID: 27349331]
L1210	IC₅₀	44 μM Compound: Celecoxib	Cytotoxicity against mouse L1210 cells after 72 hrs by MTT assay Cytotoxicity against mouse L1210 cells after 72 hrs by MTT assay	[PMID: 20451397]
LNCaP	IC₅₀	16.4 μM Compound: Celecoxib	Cytotoxicity against human LNCaP cells over expressing androgen receptor F876L mutant assessed as reduction in cell viability measured after 72 hrs by MTS assay Cytotoxicity against human LNCaP cells over expressing androgen receptor F876L mutant assessed as reduction in cell viability measured after 72 hrs by MTS assay	[PMID: 35134642]
LNCaP	IC₅₀	32.6 μM Compound: Celecoxib	Cytotoxicity against human LNCAP cells assessed as cell growth inhibition after 72 hrs by MTT assay Cytotoxicity against human LNCAP cells assessed as cell growth inhibition after 72 hrs by MTT assay	[PMID: 28057407]
LNCaP	IC₅₀	50.4 μM Compound: celecoxib	Antiproliferative activity against androgen-sensitive human LNCaP cells after 72 hrs by MTT test Antiproliferative activity against androgen-sensitive human LNCaP cells after 72 hrs by MTT test	[PMID: 15566290]
MC9	IC₅₀	0.3 μM Compound: celecoxib	Inhibition of PGF2apha production in arachidonic acid-stimulated mouse MC9 cells Inhibition of PGF2apha production in arachidonic acid-stimulated mouse MC9 cells	[PMID: 18498150]
MC9	IC₅₀	0.4 μM Compound: celecoxib	Inhibition of PGF2alpha production in mouse MC9 cells Inhibition of PGF2alpha production in mouse MC9 cells	[PMID: 18498150]
MCF7	IC₅₀	12.57 μM Compound: Celecoxib	Antiproliferative activity against human MCF7 cells incubated for 48 hrs by MTT assay Antiproliferative activity against human MCF7 cells incubated for 48 hrs by MTT assay	[PMID: 30877972]
MCF7	IC₅₀	15.4 μM Compound: Cel	Cytotoxicity against human MCF7 cells assessed as inhibition in cell growth incubated for 72 hrs by MTT assay Cytotoxicity against human MCF7 cells assessed as inhibition in cell growth incubated for 72 hrs by MTT assay	[PMID: 37567059]
MCF7	IC₅₀	15.98 μM Compound: Celecoxib	Antiproliferative activity against human cells MCF-7 assessed as reduction in cell viability incubated for 48 hrs by MTT assay Antiproliferative activity against human cells MCF-7 assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 33477020]
MCF7	IC₅₀	19.78 μM Compound: Celecoxib	Antiproliferative activity against human cells MCF-7 assessed as reduction in cell viability incubated for 24 hrs by MTT assay Antiproliferative activity against human cells MCF-7 assessed as reduction in cell viability incubated for 24 hrs by MTT assay	[PMID: 33477020]
MCF7	IC₅₀	2.56 μM Compound: Celecoxib	Antiproliferative activity against human MCF-7 cells assessed as cell growth inhibition measured after 72 hrs by SRB assay Antiproliferative activity against human MCF-7 cells assessed as cell growth inhibition measured after 72 hrs by SRB assay	[PMID: 32485532]
MCF7	IC₅₀	26.78 μM Compound: Celecoxib	Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay	[PMID: 30031652]
MCF7	IC₅₀	31.28 μM Compound: Celecoxib	Antiproliferative activity against human MCF7 cells by MTT assay Antiproliferative activity against human MCF7 cells by MTT assay	[PMID: 30216848]
MCF7	IC₅₀	40.8 μM Compound: Celecoxib	Antiproliferative activity against human MCF7 cells after 48 hrs by MTT colorimetric assay Antiproliferative activity against human MCF7 cells after 48 hrs by MTT colorimetric assay	[PMID: 22000948]
MCF7	IC₅₀	40.8 μM Compound: Celecoxib	Antitumor activity against human MCF7 cells assessed as inhibition of cell proliferation after 48 hrs by MTT assay Antitumor activity against human MCF7 cells assessed as inhibition of cell proliferation after 48 hrs by MTT assay	[PMID: 23353741]
MCF7	IC₅₀	49.66 μM Compound: Celecoxib	Antiproliferative activity against human MCF7 cells after 72 hrs by MTT assay Antiproliferative activity against human MCF7 cells after 72 hrs by MTT assay	[PMID: 29191502]
MCF7	IC₅₀	5.94 μM Compound: Celecoxib	Antiproliferative activity against human MCF7 cells after 24 hrs by MTT assay Antiproliferative activity against human MCF7 cells after 24 hrs by MTT assay	[PMID: 25866240]
MCF7	IC₅₀	50.2 μM Compound: Celecoxib	Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay	[PMID: 20451397]
MCF7	IC₅₀	6.88 μM Compound: Celecoxib	Antiproliferative activity against human MCF7 cells incubated for 48 hrs by MTT assay Antiproliferative activity against human MCF7 cells incubated for 48 hrs by MTT assay	[PMID: 26346367]
MCF7	IC₅₀	6.96 μM Compound: Celecoxib	Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay	[PMID: 30342958]
MCF7	IC₅₀	64.19 μM Compound: Celecoxib	Cytotoxicity against human MCF7 cells assessed as reduction in cell viability measured after 72 hrs by MTS assay Cytotoxicity against human MCF7 cells assessed as reduction in cell viability measured after 72 hrs by MTS assay	[PMID: 35134642]
MDA-MB-231	IC₅₀	22.79 μM Compound: Celecoxib	Antiproliferative activity against human MDA231 cells by MTT assay Antiproliferative activity against human MDA231 cells by MTT assay	[PMID: 30216848]
MDA-MB-231	IC₅₀	40 μM Compound: CCB	Cytotoxicity against human MDA-MB-231 cells after 48 hrs by MTS assay Cytotoxicity against human MDA-MB-231 cells after 48 hrs by MTS assay	[PMID: 22780961]
MDA-MB-231	IC₅₀	69.64 μM Compound: Celecoxib	Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability measured after 72 hrs by MTS assay Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability measured after 72 hrs by MTS assay	[PMID: 35134642]
NALM-6	IC₅₀	28.58 μM Compound: Celecoxib	Antiproliferative activity against human NALM-6 cells assessed as reduction in cell viability incubated for 48 hrs by CCK8 assay Antiproliferative activity against human NALM-6 cells assessed as reduction in cell viability incubated for 48 hrs by CCK8 assay	[PMID: 36395680]
PC-3	GI₅₀	4.7 x 10^-5 M Compound: Celecoxib	Anticancer activity against human PC3 cells Anticancer activity against human PC3 cells	[PMID: 18262309]
PC-3	IC₅₀	47 μM Compound: celecoxib	Antiproliferative activity against androgen-independent human PC3 cells after 72 hrs by MTT test Antiproliferative activity against androgen-independent human PC3 cells after 72 hrs by MTT test	[PMID: 15566290]
PC-3	IC₅₀	48 μM Compound: 1	Inhibition of PDK1-mediated Akt activation in human PC3 cells after 2 hrs by Western blotting analysis Inhibition of PDK1-mediated Akt activation in human PC3 cells after 2 hrs by Western blotting analysis	[PMID: 23735281]
PC-3	IC₅₀	48 μM Compound: Celecoxib	Antiproliferative activity against human PC3 cells after 72 hrs by MTT assay Antiproliferative activity against human PC3 cells after 72 hrs by MTT assay	[PMID: 17937972]
PC-3	IC₅₀	48.5 μM Compound: Celecoxib	Cytotoxicity against human PC3 cells after 72 hrs by MTT assay Cytotoxicity against human PC3 cells after 72 hrs by MTT assay	[PMID: 20451397]
RAW264.7	IC₅₀	0.0087 μM Compound: Celecoxib, Celebrex	Inhibition of COX-2 in mouse RAW264.7 cells assessed as decrease in LPS-induced PGE2 production treated prior to LPS challenge by enzyme immunoassay Inhibition of COX-2 in mouse RAW264.7 cells assessed as decrease in LPS-induced PGE2 production treated prior to LPS challenge by enzyme immunoassay	[PMID: 24656662]
RAW264.7	IC₅₀	0.1 μM Compound: Celecoxib	Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced PGE2 production Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced PGE2 production	[PMID: 22000948]
RAW264.7	IC₅₀	0.12 μM Compound: Celecoxib	Inhibition of COX-2 in mouse RAW264.7 cells assessed as decrease in LPS-induced PGE2 production Inhibition of COX-2 in mouse RAW264.7 cells assessed as decrease in LPS-induced PGE2 production	[PMID: 23353741]
RAW264.7	IC₅₀	1.28 μM Compound: Celecoxib	Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced TNF-alpha secretion after 18 hrs by sandwich ELISA Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced TNF-alpha secretion after 18 hrs by sandwich ELISA	[PMID: 24679441]
RAW264.7	IC₅₀	1.6 μM Compound: Celecoxib	Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide production preincubated for 30 mins followed by LPS stimulation measured after 24 hrs by Griess assay Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide production preincubated for 30 mins followed by LPS stimulation measured after 24 hrs by Griess assay	[PMID: 26444098]
RAW264.7	IC₅₀	1.84 μM Compound: Celecoxib	Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide production after 18 hrs by griess reaction analysis Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide production after 18 hrs by griess reaction analysis	[PMID: 24679441]
RAW264.7	IC₅₀	10.69 μM Compound: Celecoxib	Inhibition of LPS-induced TNFalpha production in mouse RAW264.7 cells preincubated for 2 hrs followed by LPS stimulation and measured after 20 hrs by ELISA Inhibition of LPS-induced TNFalpha production in mouse RAW264.7 cells preincubated for 2 hrs followed by LPS stimulation and measured after 20 hrs by ELISA	[PMID: 33892270]
RAW264.7	IC₅₀	11.17 μM Compound: Celecoxib	Inhibition of LPS-induced IL-6 production in mouse RAW264.7 cells preincubated for 2 hrs followed by LPS stimulation and measured after 20 hrs by ELISA Inhibition of LPS-induced IL-6 production in mouse RAW264.7 cells preincubated for 2 hrs followed by LPS stimulation and measured after 20 hrs by ELISA	[PMID: 33892270]
RAW264.7	IC₅₀	11.73 μM Compound: Celecoxib	Antioxidant activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced intracellular ROS production preincubated for 2 hrs followed by LPS stimulation and measured after 20 hrs by DCFH-DA staining based fluorescence analysis Antioxidant activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced intracellular ROS production preincubated for 2 hrs followed by LPS stimulation and measured after 20 hrs by DCFH-DA staining based fluorescence analysis	[PMID: 33892270]
RAW264.7	IC₅₀	11130 μM Compound: Celecoxib	Cytotoxicity against mouse RAW264.7 cells assessed as cell viability by propidium iodide staining based FACS-flow cytometry Cytotoxicity against mouse RAW264.7 cells assessed as cell viability by propidium iodide staining based FACS-flow cytometry	[PMID: 22494844]
RAW264.7	IC₅₀	12.2 μM Compound: Celecoxib	Inhibition of TNF-alpha production in LPS-induced mouse RAW264.7 cells pretreated for 1 hr followed by LPS stimulation and measured after 24 hrs by ELISA Inhibition of TNF-alpha production in LPS-induced mouse RAW264.7 cells pretreated for 1 hr followed by LPS stimulation and measured after 24 hrs by ELISA	[PMID: 37561816]
RAW264.7	IC₅₀	12090 μM Compound: Celecoxib	Inhibition of LPS-induced NO production in mouse RAW264.7 cells after 24 hrs by Griess assay Inhibition of LPS-induced NO production in mouse RAW264.7 cells after 24 hrs by Griess assay	[PMID: 22494844]
RAW264.7	IC₅₀	13.7 μM Compound: Celecoxib	Inhibition of IL-6 production in LPS-induced mouse RAW264.7 cells pretreated for 1 hr followed by LPS stimulation and measured after 24 hrs by ELISA Inhibition of IL-6 production in LPS-induced mouse RAW264.7 cells pretreated for 1 hr followed by LPS stimulation and measured after 24 hrs by ELISA	[PMID: 37561816]
RAW264.7	IC₅₀	14.6 μM Compound: Celecoxib	Inhibition of IL-1beta production in LPS-induced mouse RAW264.7 cells pretreated for 1 hr followed by LPS stimulation and measured after 24 hrs by ELISA Inhibition of IL-1beta production in LPS-induced mouse RAW264.7 cells pretreated for 1 hr followed by LPS stimulation and measured after 24 hrs by ELISA	[PMID: 37561816]
RAW264.7	IC₅₀	16.5 μM Compound: Celecoxib	Anti-inflammatory activity against mouse RAW264.7 cells assessed as inhibition of LPS-induced NO production measured after 24 hrs incubation by Griess analysis Anti-inflammatory activity against mouse RAW264.7 cells assessed as inhibition of LPS-induced NO production measured after 24 hrs incubation by Griess analysis	[PMID: 37224762]
RAW264.7	IC₅₀	16.52 μM Compound: Celecoxib	Antiinflammatory activity in LPS-activated mouse RAW264.7 cells assessed as inhibition of ROS production by DCFH-DA staining based assay Antiinflammatory activity in LPS-activated mouse RAW264.7 cells assessed as inhibition of ROS production by DCFH-DA staining based assay	[PMID: 37182334]
RAW264.7	IC₅₀	17.89 μM Compound: Celecoxib	Antiinflammatory activity in LPS-induced mouse RAW264.7 cells assessed as inhibition of NO production incubated for 24 hrs in presence of LPS by griess reagent based assay Antiinflammatory activity in LPS-induced mouse RAW264.7 cells assessed as inhibition of NO production incubated for 24 hrs in presence of LPS by griess reagent based assay	[PMID: 37561816]
RAW264.7	IC₅₀	17.94 μM Compound: Celecoxib	Inhibition of IL-1beta production in LPS-induced mouse RAW264.7 cells incubated for 24 hrs in presence of LPS by ELISA Inhibition of IL-1beta production in LPS-induced mouse RAW264.7 cells incubated for 24 hrs in presence of LPS by ELISA	[PMID: 37561816]
RAW264.7	IC₅₀	17 μg/mL Compound: Celecoxib	Cytotoxicity against mouse RAW264.7 cells after 8 hrs by MTT assay Cytotoxicity against mouse RAW264.7 cells after 8 hrs by MTT assay	[PMID: 19398640]
RAW264.7	IC₅₀	19.58 μM Compound: Celecoxib	Inhibition of LPS-induced NO production in mouse RAW264.7 cells preincubated for 2 hrs followed by LPS stimulation and measured after 20 hrs by DAF-FM based fluorescence analysis Inhibition of LPS-induced NO production in mouse RAW264.7 cells preincubated for 2 hrs followed by LPS stimulation and measured after 20 hrs by DAF-FM based fluorescence analysis	[PMID: 33892270]
RAW264.7	IC₅₀	2.3 μM Compound: Celecoxib	Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced NO production pretreated with compound for 2 hrs followed by LPS stimulation measured after 18 hrs by gGriess reagent based assay Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced NO production pretreated with compound for 2 hrs followed by LPS stimulation measured after 18 hrs by gGriess reagent based assay	[PMID: 34658231]
RAW264.7	IC₅₀	21.1 μM Compound: Celecoxib	Antiinflammatory activity in LPS-induced mouse RAW264.7 cells assessed as inhibition of NO production pretreated for 1 hr followed by LPS stimulation and measured after 24 hrs by griess reagent based assay Antiinflammatory activity in LPS-induced mouse RAW264.7 cells assessed as inhibition of NO production pretreated for 1 hr followed by LPS stimulation and measured after 24 hrs by griess reagent based assay	[PMID: 37561816]
RAW264.7	IC₅₀	22.89 μM Compound: Celecoxib	Antiinflammatory activity in LPS-activated mouse RAW264.7 cells assessed as inhibition of NO production preincubated for 2 hrs followed by LPS addition measured after 20 hrs by DAF-FM staining based assay Antiinflammatory activity in LPS-activated mouse RAW264.7 cells assessed as inhibition of NO production preincubated for 2 hrs followed by LPS addition measured after 20 hrs by DAF-FM staining based assay	[PMID: 37182334]
RAW264.7	IC₅₀	23.09 μM Compound: Celecoxib	Anti inflammatory activity in LPS-induced mouse RAW264.7 cells assessed as inhibition of NO production preincubated with LPS for 4 hrs followed by compound addition and measured after 18 hrs by griess reagent based assay Anti inflammatory activity in LPS-induced mouse RAW264.7 cells assessed as inhibition of NO production preincubated with LPS for 4 hrs followed by compound addition and measured after 18 hrs by griess reagent based assay	[PMID: 37146344]
RAW264.7	IC₅₀	3.12 μM Compound: Celecoxib	Antiinflammatory activity in LPS-activated mouse RAW264.7 cells assessed as inhibition of IL-6 production preincubated for 2 hrs followed by LPS addition measured after 20 hrs by ELISA method Antiinflammatory activity in LPS-activated mouse RAW264.7 cells assessed as inhibition of IL-6 production preincubated for 2 hrs followed by LPS addition measured after 20 hrs by ELISA method	[PMID: 37182334]
RAW264.7	IC₅₀	3.12 μM Compound: Cpd I	Anti-inflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced TNF-alpha production preincubated for 2 hrs followed by LPS stimulation and measured after 20 hrs by ELISA Anti-inflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced TNF-alpha production preincubated for 2 hrs followed by LPS stimulation and measured after 20 hrs by ELISA	[PMID: 37611534]
RAW264.7	IC₅₀	34.3 μM Compound: Celecoxib	Antiinflammatory activity against mouse RAW264.7 cells assessed as inhibition of cell growth Antiinflammatory activity against mouse RAW264.7 cells assessed as inhibition of cell growth	[PMID: 33454546]
RAW264.7	IC₅₀	36.04 μM Compound: Celecoxib	Inhibition of IL-6 production in LPS-induced mouse RAW264.7 cells incubated for 24 hrs in presence of LPS by ELISA Inhibition of IL-6 production in LPS-induced mouse RAW264.7 cells incubated for 24 hrs in presence of LPS by ELISA	[PMID: 37561816]
RAW264.7	IC₅₀	4.14 μM Compound: Celecoxib	Antiinflammatory activity in LPS-activated mouse RAW264.7 cells assessed as inhibition of TNF-alpha production preincubated for 2 hrs followed by LPS addition measured after 20 hrs by ELISA method Antiinflammatory activity in LPS-activated mouse RAW264.7 cells assessed as inhibition of TNF-alpha production preincubated for 2 hrs followed by LPS addition measured after 20 hrs by ELISA method	[PMID: 37182334]
RAW264.7	IC₅₀	4.36 μM Compound: Cpd I	Anti-inflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced IL-6 production preincubated for 2 hrs followed by LPS stimulation and measured after 20 hrs by ELISA Anti-inflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced IL-6 production preincubated for 2 hrs followed by LPS stimulation and measured after 20 hrs by ELISA	[PMID: 37611534]
RAW264.7	IC₅₀	41.18 μM Compound: Celecoxib	Inhibition of TNF-alpha production in LPS-induced mouse RAW264.7 cells incubated for 24 hrs in presence of LPS by ELISA Inhibition of TNF-alpha production in LPS-induced mouse RAW264.7 cells incubated for 24 hrs in presence of LPS by ELISA	[PMID: 37561816]
RAW264.7	IC₅₀	49.37 μM Compound: Cpd I	Antioxidant activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced ROS production preincubated with compound for 2 hrs followed by LPS stimulation and measured after 20 hrs by DCFH-DA probe based fluorescence analysis Antioxidant activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced ROS production preincubated with compound for 2 hrs followed by LPS stimulation and measured after 20 hrs by DCFH-DA probe based fluorescence analysis	[PMID: 37611534]
RAW264.7	IC₅₀	50.9 μM Compound: Cpd I	Antioxidant activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced NO production preincubated with compound for 2 hrs followed by LPS stimulation and measured after 20 hrs by fluorescence microscopic analysis Antioxidant activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced NO production preincubated with compound for 2 hrs followed by LPS stimulation and measured after 20 hrs by fluorescence microscopic analysis	[PMID: 37611534]
RAW264.7	IC₅₀	7.46 μM Compound: Celecoxib	Inhibition of LPS-induced 15(S)-HETE production in mouse RAW264.7 cells preincubated for 2 hrs followed by LPS stimulation and measured after 20 hrs by ELISA Inhibition of LPS-induced 15(S)-HETE production in mouse RAW264.7 cells preincubated for 2 hrs followed by LPS stimulation and measured after 20 hrs by ELISA	[PMID: 33892270]
SH-SY5Y	IC₅₀	5 μM Compound: Celecoxib	Antineurotoxicity in human SH-SY5Y cells assessed as inhibition human THP1 cell supernatant-induced cytotoxicity compound pretreated 24 to 48 hrs to THP1 cells measured after 72 hrs of supernatant addition Antineurotoxicity in human SH-SY5Y cells assessed as inhibition human THP1 cell supernatant-induced cytotoxicity compound pretreated 24 to 48 hrs to THP1 cells measured after 72 hrs of supernatant addition	[PMID: 20138770]
SMMC-7721	IC₅₀	5.96 μM Compound: Celecoxib	Antiproliferative activity against human SMMC7721 cells after 48 hrs by MTT assay Antiproliferative activity against human SMMC7721 cells after 48 hrs by MTT assay	[PMID: 28720504]
SW480	IC₅₀	6.9 μM Compound: Celecoxib	Cytotoxicity against COX-2 negative human SW480 cells assessed as growth inhibition by CellTiter-96 AQueous assay Cytotoxicity against COX-2 negative human SW480 cells assessed as growth inhibition by CellTiter-96 AQueous assay	[PMID: 24295787]
Sf9	IC₅₀	0.036 μM Compound: Celecoxib	In vitro inhibitory activity against human recombinant prostaglandin G/H synthase 2 expressed in sf-9 cells infected with baculovirus In vitro inhibitory activity against human recombinant prostaglandin G/H synthase 2 expressed in sf-9 cells infected with baculovirus	[PMID: 15026050]
Sf9	IC₅₀	0.036 μM Compound: celecoxib	Inhibitory activity against human Prostaglandin G/H synthase 2 expressed in sf-9 cells infected with baculovirus Inhibitory activity against human Prostaglandin G/H synthase 2 expressed in sf-9 cells infected with baculovirus	[PMID: 14698190]
Sf9	IC₅₀	0.04 μM Compound: 2	Inhibition of recombinant human COX-2 expressed in Baculovirus infected sf9 cells using arachidonic acid as substrate preincubated for 10 mins followed by substrate addition measured after 10 mins by ELISA Inhibition of recombinant human COX-2 expressed in Baculovirus infected sf9 cells using arachidonic acid as substrate preincubated for 10 mins followed by substrate addition measured after 10 mins by ELISA	[PMID: 30396033]
Sf9	IC₅₀	0.08 μM Compound: celecoxib	Inhibition of human COX2 expressed in sf9 cells Inhibition of human COX2 expressed in sf9 cells	[PMID: 16252917]
Sf9	IC₅₀	63 nM Compound: 3	Inhibition of human COX2 expressed in baculovirus-infected SF9 cells assessed as inhibition of arachidonic acid-stimulated PGE2 production treated 1 hr before arachidonic acid challenge by enzyme immunoassay Inhibition of human COX2 expressed in baculovirus-infected SF9 cells assessed as inhibition of arachidonic acid-stimulated PGE2 production treated 1 hr before arachidonic acid challenge by enzyme immunoassay	[PMID: 19520573]
Sf9	IC₅₀	> 100 μM Compound: celecoxib	Inhibition of human COX1 expressed in sf9 cells Inhibition of human COX1 expressed in sf9 cells	[PMID: 16252917]
Sf9	IC₅₀	> 1000 nM Compound: 3	Inhibition of human COX1 expressed in baculovirus-infected SF9 cells assessed as inhibition of arachidonic acid-stimulated PGE2 production treated 1 hr before arachidonic acid challenge by enzyme immunoassay Inhibition of human COX1 expressed in baculovirus-infected SF9 cells assessed as inhibition of arachidonic acid-stimulated PGE2 production treated 1 hr before arachidonic acid challenge by enzyme immunoassay	[PMID: 19520573]
THP-1	EC₅₀	50 μM Compound: Celecoxib	Cytotoxicity against LPS and IFN-gamma-stimulated human THP1 cells after 24 hrs Cytotoxicity against LPS and IFN-gamma-stimulated human THP1 cells after 24 hrs	[PMID: 20138770]
THP-1	EC₅₀	50 μM Compound: Celecoxib	Cytotoxicity against human THP1 cells assessed as reduction in cell viability Cytotoxicity against human THP1 cells assessed as reduction in cell viability	[PMID: 20609589]
THP-1	IC₅₀	5 μM Compound: Celecoxib	Neuroprotective activity against LPS and IFN-gamma-stimulated neurotoxin production in human THP1 cell assessed as inhibition of THP1 cell secretion-induced toxicity to human SH-SY5Y cells after 72 hrs by MTT assay Neuroprotective activity against LPS and IFN-gamma-stimulated neurotoxin production in human THP1 cell assessed as inhibition of THP1 cell secretion-induced toxicity to human SH-SY5Y cells after 72 hrs by MTT assay	[PMID: 20609589]
THP-1	IC₅₀	70 μM Compound: Celecoxib	Antiinflammatory activity in human THP1 cells assessed as reduction in LPS and IFN-gamma-induced MCP level after 24 hrs Antiinflammatory activity in human THP1 cells assessed as reduction in LPS and IFN-gamma-induced MCP level after 24 hrs	[PMID: 20609589]
U-251	IC₅₀	> 40 μM Compound: Celecoxib	Antiproliferative activity against human U-251 cells assessed as growth inhibition incubated for 72 hrs by CCK-8 assay Antiproliferative activity against human U-251 cells assessed as growth inhibition incubated for 72 hrs by CCK-8 assay	[PMID: 34091208]
U-87MG ATCC	IC₅₀	> 40 μM Compound: Celecoxib	Antiproliferative activity against human U-87 MG cells assessed as growth inhibition incubated for 72 hrs by CCK-8 assay Antiproliferative activity against human U-87 MG cells assessed as growth inhibition incubated for 72 hrs by CCK-8 assay	[PMID: 34091208]
U-937	IC₅₀	0.05 μM Compound: Celecoxib	Inhibition of COX-1 in U-937 (human lymphoma) cell microsomes. Inhibition of COX-1 in U-937 (human lymphoma) cell microsomes.	[PMID: 10576685]
U-937	IC₅₀	5.1 μM Compound: 2	Inhibition of Prostaglandin G/H synthase 1 in U-937 cells from human histiocytic lymphoma Inhibition of Prostaglandin G/H synthase 1 in U-937 cells from human histiocytic lymphoma	[PMID: 11462976]
U-937	IC₅₀	5.1 μM Compound: 2 (celecoxib)	In vitro inhibitory activity against human Prostaglandin G/H synthase 1 (COX-1) in U-937 cells In vitro inhibitory activity against human Prostaglandin G/H synthase 1 (COX-1) in U-937 cells	[PMID: 12877584]
UACC-903	IC₅₀	55.6 μM Compound: Celecoxib	Anticancer activity against human UACC-903 cells assessed as cell growth inhibition incubated for 72 hrs by MTS assay Anticancer activity against human UACC-903 cells assessed as cell growth inhibition incubated for 72 hrs by MTS assay	[PMID: 34217061]
Vero	IC₅₀	60.63 μM Compound: Celecoxib	Cytotoxicity against African green monkey Vero cells assessed as reduction in cell viability measured after 72 hrs by MTS assay Cytotoxicity against African green monkey Vero cells assessed as reduction in cell viability measured after 72 hrs by MTS assay	[PMID: 35134642]
WI-38	IC₅₀	432.9 μM Compound: Celecoxib	Cytotoxicity against human WI-38 cells assessed as reduction in cell viability after 72 hrs by SRB assay Cytotoxicity against human WI-38 cells assessed as reduction in cell viability after 72 hrs by SRB assay	[PMID: 32485532]
WM-115	IC₅₀	55.6 μM Compound: Celecoxib	Anticancer activity against human WM-115 cells assessed as cell growth inhibition incubated for 72 hrs by MTS assay Anticancer activity against human WM-115 cells assessed as cell growth inhibition incubated for 72 hrs by MTS assay	[PMID: 34217061]

In Vitro

The selective cyclooxygenase-2 (COX-2) inhibitor Celecoxib (10-75 μM) inhibits the proliferation of the NPC cell lines in a dose-dependent manner. Celecoxib (25 and 50 μM) induces apoptosis and cell-cycle arrest at the G₀/G₁ checkpoint in the NPC cell lines, which is associated with significantly reduced STAT3 phosphorylation. The genes downstream of STAT3 (ie, Survivin, Mcl-1, Bcl-2 and Cyclin D1) are significantly down-regulated after exposure to Celecoxib (25 and 50 μM)^[2].
Targeting the YAP/TAZ transcriptional target cyclooxygenase 2 (COX-2) using celecoxib inhibits cell proliferation and tumorigenesis in NF2 mutant cells^[6].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Solvant et solubilité

In Vitro:

DMSO : ≥ 50 mg/mL (131.11 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

*"≥" means soluble, but saturation unknown.

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	2.6221 mL	13.1106 mL	26.2213 mL
5 mM	0.5244 mL	2.6221 mL	5.2443 mL
10 mM	0.2622 mL	1.3111 mL	2.6221 mL

View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (6.56 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (6.56 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil
Solubility: ≥ 2.5 mg/mL (6.56 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.
Protocol 4

Add each solvent one by one: 5% DMSO 95% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (6.56 mM); Clear solution

Pureté et documentation

Purity: 99.89%

Fiche technique (285 KB) SDS (623 KB)

COA (254 KB) HNMR (258 KB) RP-HPLC (245 KB) LCMS (93 KB)

Instruction de manipulation (2659 KB)

Références

[1]. Penning TD, et al. Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benze nesulfonamide (SC-58635, celecoxib). J Med Chem. 1997 [Content Brief]

[2]. Liu DB, et al. Celecoxib induces apoptosis and cell-cycle arrest in nasopharyngeal carcinoma cell lines via inhibition of STAT3 phosphorylation. Acta Pharmacol Sin. 2012 May;33(5):682-90. [Content Brief]

[3]. Suri A, et al. The effect of celecoxib on tumor growth in ovarian cancer cells and a genetically engineered mouse model of serous ovarian cancer. Oncotarget. 2016 Apr 8. [Content Brief]

[4]. Hou XL, et al. Combination of fasudil and celecoxib promotes the recovery of injured spinal cord in rats better than celecoxib or fasudil alone. Neural Regen Res. 2015 Nov;10(11):1836-40. [Content Brief]

[5]. Liu C, et al. Celecoxib alleviates nonalcoholic fatty liver disease by restoring autophagic flux. Sci Rep. 2018 Mar 7;8(1):4108. [Content Brief]

[6]. Pobbati AV, et al. A combat with the YAP/TAZ-TEAD oncoproteins for cancer therapy. Theranostics. 2020 Feb 18;10(8):3622-3635. [Content Brief]

Você também pode estar interessado nos seguintes produtos:

Referência

Descrição

Cond.

Price Bef. VAT

EIA-CAMP-5

Human cAMP ELISA Kit

5PlateKit

EIA-CAMP-1

Human cAMP ELISA Kit

1PlateKit

Celecoxib [169590-42-5]

Referência HY-14398-1g

Contactar o distribuidor local :

Marca : MedChemExpress

Contactar o distribuidor local :

Celecoxib Related Antibodies

Você também pode estar interessado nos seguintes produtos: